NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal...
Pharmaceutical
PharmaCord Announces Leadership Expansion, Appointing Rob Brown to Chief Growth Officer
JEFFERSONVILLE, IN / ACCESSWIRE / April 17, 2024 / PharmaCord LLC, a leading provider of patient support services for the...
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to presentSOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke...
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBAPITTSBURGH, Pa., April 17,...
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company...
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP...
Zylö announces the creation and spinout of Atticus Pharma Inc.
Atticus to focus on biopharma applications of the innovative ‘Powered by Z-pod®’ topical-delivery platform GREENVILLE, SC, April 17, 2024 (GLOBE...
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”...
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ETWALTHAM, Mass., April 17, 2024 (GLOBE...
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe...
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the...
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against...
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health...
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) –...
Q1 2024 Revenue and Business Update
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update...
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...